Objective: This study aims to evaluate potential pancreas endocrine damage due to SARS-CoV-2 by measuring β-cell autoantibodies in COVID-19 patients. Subjects and methods: Between June and July 2020, 95 inpatients with a positive COVID-19 test result after polymerase-chain-reaction (PCR) and who met the inclusion criteria were enrolled in our study. Laboratory parameters that belong to glucose metabolism and β-cell autoantibodies, including anti-islet, anti-glutamic acid decarboxylase, and anti-insulin autoantibodies, were measured. β-cell autoantibodies levels of the patients were measured during COVID-19 diagnosis. Positive results were reevaluated in the 3rd month of control. Results: In the initial evaluation, 4 (4.2%) patients were positive for anti-islet autoantibody. Only one (1.1%) patient was positive for anti-glutamic acid decarboxylase autoantibody. No patient had positive results for anti-insulin autoantibody. FPG, HbA1c, and C-peptide levels were similar in patients who were split into groups regarding the initial positive or negative status of anti-islet and anti-GAD autoantibodies (p>0.05). In the 3rd month after the initial measurements, anti-islet autoantibody positivity of 2 (50%) of 4 patients and anti-glutamic acid decarboxylase positivity of 1 (100%) patient were persistent. Finally, 3 (3.1%) patients in the whole group were positive for anti-islet autoantibody in the 3rd month of control. No difference was determined between the initial and the 3rd month of parameters of glucose metabolism. Conclusion: Following an ongoing autoantibody positivity in the present study brings the mind that SARS-CoV-2 may be responsible for the diabetogenic effect. Clinicians should be aware of autoantibody-positive DM as a potential autoimmune complication in patients with SARS-CoV-2.
Introduction The prognostic nutritional index (PNI) is calculated using total serum lymphocyte counts and albumin levels. We aimed to analyze the role of PNI in predicting intensive care unit (ICU) referral and mortality in patients with Crimean Congo hemorrhagic fever (CCHF). Materials and Methods Our target population was adult (age >18) patients who presented between March 2015 and October 2021 within 5 days of symptom emergence and were diagnosed with CCHF. The predictive value of PNI was analyzed by the receiver operating curve analysis. The patients were categorized based on the severity grading scores (SGS) as mild, moderate, and severe. The relationship between PNI and ICU referral and mortality was analyzed by logistic regression analysis. Results Overall, 115 patients with the diagnosis of CCHF were included. 13.9% (n = 16) of the patients were referred to ICU while 11.3% (n = 13) died. A comparison of the patients with different SGS grades revealed that they were significantly different regarding PNI (p < 0.001). There was a significant negative correlation between PNI and SGS (r = −0.662; p < 0.001). PNI had a PV regarding ICU referral and mortality ([area under the curve [AUC] = 0.723, 95% confidence interval [CI]: 0.609–0.836, p = 0.004 [AUC = 0.738, 95% CI: 0.613–0.863, p = 0.005]). The PNI threshold was 36.1 for ICU referral and mortality. The rates of female patients, hospitalization periods longer than 1 week, platelet apheresis replacement, diabetes mellitus, bleeding history, ICU admission, and mortality were significantly higher in patients with a PNI of lower than 36.1 (p < 0.05). Conclusion PNI can predict ICU referral and mortality in patients admitted due to CCHF.
Aim: It has been known for a long time that systemic inflammation is an important risk factor in cancer development.Colorectal cancer (CRC) is one of the most common causes of cancer-related morbidity and mortality in the world. In this study, we aimed to compare the inflammatory parameters tested in CRC patients at the time of diagnosis such as systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV) with those of the healthy control group. Materials and Methods:The data of 162 patients diagnosed with CRC in the internal medicine clinic between 2012-2016 were analysed retrospectively and a total of 139 patients who met the inclusion criteria were included in the study. Hemogram values, histopathology and tumour stage according to TNM classification of all patients at the time of diagnosis were recorded. The patients' neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocytemonocyte ratio (LMR), SII and PIV were calculated using hemogram parameters such as neutrophils, monocytes, platelets and lymphocytes.Results: A total of 139 CRC patients and 139 healthy control subjects with similar age and sex distribution were included in the study. The mean age of all subjects included in the study was 61.7±11.8 years, and 170 subjects (61.2%) were male.In the CRC group, SII, PIV, NLR, and PLR levels were significantly higher, and LMR level was significantly lower than the control group (p<0.001, p<0.001, p<0.001, p<0.001, p=0.001, respectively). When the CRC group was divided according to the disease stage, it was found that SII and PIV levels of all stages were significantly higher than the control group (p= 0.029, p<0.001, p= 0.001, p= 0.002 for SII, p= 0.034, p<0.001, p= 0.002, p= 0.014 for PIV). Conclusion:In addition to colonoscopy screening in patients with CRC, whose early diagnosis is very important, SII and PIV values that do not require an additional cost and can be measured in routine hemogram tests can also be taken into consideration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.